Merck & Co., Inc. (MRK)[Tv]

Key Developments

• Merck voluntarily withdrew its Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC) due to safety concerns, including a 12.4% rate of treatment-related interstitial lung disease and two fatal cases—a major strategic setback that exposes deep vulnerabilities in Merck’s ADC pipeline and raises serious questions about its ability to deliver next-generation oncology therapies beyond Keytruda.

• The Dutch court blocked Merck’s subcutaneous Keytruda formulation (KEYTRUDA QLEX) in eight major European markets over a patent infringement ruling by Halozyme Therapeutics—a critical legal blow that threatens a key growth driver, undermines Merck’s IP strategy, and jeopardizes commercial momentum in a high-value region.

• Merck and Moderna’s intismeran autogene (V940), a personalized mRNA cancer vaccine, achieved both primary and secondary endpoints in a pivotal phase 3 trial when combined with Keytruda—marking the first time an mRNA therapy surpassed a PD-1 inhibitor in late-stage oncology, validating Merck’s platform and positioning it at the forefront of a potentially $50B+ market.

Key Developments

• Merck voluntarily withdrew its BLA for ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer due to safety concerns, including a 12.4% rate of treatment-related interstitial lung disease and two fatal cases – This retreat marks a major strategic setback, exposing deep vulnerabilities in Merck’s antibody-drug conjugate (ADC) platform and raising urgent questions about its ability to deliver next-generation oncology therapies beyond Keytruda.

• The European Medicines Agency (EMA) issued a positive recommendation for KEYTRUDA plus Padcev in resectable muscle-invasive bladder cancer, potentially paving the way for European Commission approval by Q4 2026 – This landmark regulatory validation solidifies Merck’s first-mover advantage in a high-need, high-volume indication with ~56,000 eligible patients.

• Tulisokibart achieved 72% HiSCR50 response rates in Phase 2b for moderate to severe hidradenitis suppurativa, representing a breakthrough in dermatology and a potential cornerstone for a new immunology franchise beyond oncology – This is a rare late-stage success and validates Merck’s bet on anti-TL1A targeting in immuno-fibrosis.

Key Developments

• EMA issues positive CHMP opinion for KEYTRUDA + Padcev in resectable muscle-invasive bladder cancer, marking a potential first-in-class PD-1 inhibitor plus ADC regimen in Europe and setting the stage for European Commission approval by Q4 2026—a landmark regulatory validation of Merck’s combination strategy and a major step toward first-mover commercial advantage in a high-need, high-volume indication.

• Tulisokibart achieves pivotal Phase III success in ulcerative colitis (ATLAS-UC trial), meeting primary endpoint for clinical remission at week 12—a breakthrough that cements Merck’s legitimacy as a true innovator in IBD with a novel mechanism poised to disrupt the anti-TNF space and capture first-line therapy share.

• FDA approves LIPFENDRA, the first oral PCSK9 inhibitor, delivering a transformative diversification into cardiometabolic health with massive long-term commercial potential and positioning Merck for sustainable growth beyond oncology, even as Keytruda-dependent growth faces headwinds.

Key Developments

• Phase 3 INTerpath-001 trial success for intismeran autogene + Keytruda in high-risk melanoma – This landmark result marked the first-ever statistically significant improvement in recurrence-free and distant-metastasis-free survival for an individualized mRNA cancer vaccine, validating Merck’s next-generation immuno-oncology platform and triggering a $43 billion market surge in a single day.
• FDA approval of Padcev (Pfizer/Astellas) + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility – Backed by 35% reduction in mortality risk, this approval significantly expands Keytruda’s addressable population and reinforces Merck’s dominance in combination immunotherapy.
• Positive Phase 3 results for Tulisokibart (MK-7240) in ulcerative colitis (ATLAS-UC trial) – The drug met its primary endpoint for clinical remission, positioning it as a potential blockbuster in the high-growth IBD market and signaling a successful strategic pivot beyond oncology.
• FDA approval of LIPFENDRA, the first oral PCSK9 inhibitor – This first-in-class therapy offers a patient-friendly alternative in cardiometabolic health, delivering a transformative diversification play and unlocking long-term commercial potential beyond Merck’s oncology-centric past.
• Summit Therapeutics reports transformative Phase III data for ivonescimab, showing superior overall survival vs. Keytruda in NSCLC with high PD-L1 expression – This is a direct challenge to Keytruda’s dominance and threatens to erode Merck’s core revenue stream if global approvals follow.

Key Developments

• FDA approval of LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor, marks a transformative milestone in cardiometabolic therapy, positioning Merck as a leader in a high-growth, underserved cardiovascular market with significant commercial potential.
• Phase 3 INTerpath-001 trial success for intismeran autogene + Keytruda in resected high-risk melanoma delivers the first-ever successful Phase 3 result for an individualized mRNA neoantigen cancer vaccine—validating Merck’s pivot to next-generation personalized immuno-oncology and reshaping its long-term growth narrative.
• The FDA’s acceptance of the sBLA for ENFLONSIA, a pediatric RSV vaccine, with a March 22, 2027 PDUFA decision, represents a pivotal step in Merck’s diversification strategy and a potential inflection point for its future revenue base beyond oncology.
• Merck’s strategic licensing of HRS-5346, a cardiovascular drug developed entirely in China, signals a bold global innovation push but raises significant geopolitical and regulatory risks amid increasing U.S. scrutiny over Chinese technology and supply chain sovereignty.
• Merck’s $43 billion market cap surge in a single day following the intismeran trial success underscores a radical shift in investor perception—from a legacy blockbuster-dependent firm to a high-conviction growth engine in precision oncology.

Critical News